Safety, Tolerability, and Distribution of Topical Laquinimod Eye Drops , an Innovative ImmunomodulatOr Targeting Aryl hydrocarboN Receptor (AhR): The LION Study

The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.

Start Date01 Apr 2024

Sponsor / Collaborator

Stanford University

NCT05187403 / CompletedPhase 1

A Placebo-Controlled, Double-masked Phase-1 Study in Healthy Subjects Investigating the Safety and Tolerability of Laquinimod Eye Drops

This is a Phase 1 randomized, double-masked, placebo-controlled study performed with healthy participants to assess the safety and tolerability of laquinimod eye-drops.

Start Date09 Dec 2021

Sponsor / Collaborator

Active Biotech AB

NL-OMON43112 / CompletedNot Applicable

A randomized, open-label, two-way crossover study to assess the relative bioavailability of Laquinimod 0.6 mg test tablet versus Laquinimod 0.6 mg reference capsule after single dose administration with a single sequence extension to assess the pharmacokinetics of Laquinimod and its metabolites after single and multiple oral 0.6 mg dose administration in healthy subjects. - Bioavailability study Laquinimod test tablets

Start Date05 Oct 2016

Sponsor / Collaborator

Teva Pharmaceutical Industries Ltd.

100 Clinical Results associated with Laquinimod

100 Translational Medicine associated with Laquinimod

100 Patents (Medical) associated with Laquinimod

189

Literatures (Medical) associated with Laquinimod

01 Mar 2024·The Lancet. Neurology

Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Article

Author: DeMichele, Giuseppe ; Kulisevsky Bojarski, Jaime ; Klempir, Jiri ; LeDoux, Mark S ; Muñoz García, José Esteban ; Squitieri, Ferdinando ; Berganzo Corrales, Koldo ; Rickards, Hugh ; McDonell, Katherine ; Borowsky, Beth ; Hayden, Michael ; Miedzybrodzka, Zofia ; Soliveri, Paola ; López-Sendón Moreno, José Luis ; Nance, Martha ; Anderson, Karen E ; Loupe, Pippa ; Li, Thomas ; Priller, Josef ; Leavitt, Blair R ; Quarrell, Oliver William John ; Craufurd, David ; Volkinshtein, Rita ; Feigin, Andrew ; Suchowersky, Oksana ; Raymond, Lynn ; Roos, Raymund A C ; Cortelli, Pietro ; Reilmann, Ralf ; Zalyalova, Zuleykha ; Tabrizi, Sarah J ; Saft, Carsten ; Wickenberg, Anna ; Orth, Michael ; Gustov, Aleksandr ; Guttman, Mark ; Gordon, Mark Forrest ; Rynkowski, Gail ; Lahiri, Nayana ; Winkler, Juergen ; Marshall, Frederick J ; Mariotti, Caterina ; Weindl, Adolf ; Illarioshkin, Sergey ; Kamholz, John ; Bang, Jee ; Sanchez-Ramos, Juan ; Komati, Suresh K ; Schubert, Robin ; García Moreno, José Manuel ; Racette, Brad ; Ruddy, Deborah ; Marder, Karen S ; Mendis, Tilak ; Savola, Juha-Matti ; Segro, Victoria ; Stout, Julie C ; Correira Guedes, Leonor ; Corey-Bloom, Jody ; Davies, Rhys Richard ; Geschwind, Michael D ; Piccini, Paola ; Cubo, Esther

BACKGROUND:

Laquinimod modulates CNS inflammatory pathways thought to be involved in the pathology of Huntington's disease. Studies with laquinimod in transgenic rodent models of Huntington's disease suggested improvements in motor function, reduction of brain volume loss, and prolonged survival. We aimed to evaluate the safety and efficacy of laquinimod in improving motor function and reducing caudate volume loss in patients with Huntington's disease.

METHODS:

LEGATO-HD was a multicentre, double-blind, placebo-controlled, phase 2 study done at 48 sites across ten countries (Canada, Czech Republic, Germany, Italy, Netherlands, Portugal, Russia, Spain, UK, and USA). Patients aged 21-55 years with a cytosine-adenosine-guanine (CAG) repeat length of between 36 and 49 who had symptomatic Huntington's disease with a Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) of higher than 5 and a Total Functional Capacity score of 8 or higher were randomly assigned (1:1:1:1) by centralised interactive response technology to laquinimod 0·5 mg, 1·0 mg, or 1·5 mg, or to matching placebo, administered orally once daily over 52 weeks; people involved in the randomisation had no other role in the study. Participants, investigators, and study personnel were masked to treatment assignment. The 1·5 mg group was discontinued before recruitment was finished because of cardiovascular safety concerns in multiple sclerosis studies. The primary endpoint was change from baseline in the UHDRS-TMS and the secondary endpoint was percent change in caudate volume, both comparing the 1·0 mg group with the placebo group at week 52. Primary and secondary endpoints were assessed in the full analysis set (ie, all randomised patients who received at least one dose of study drug and had at least one post-baseline UHDRS-TMS assessment). Safety measures included adverse event frequency and severity, and clinical and laboratory examinations, and were assessed in the safety analysis set (ie, all randomised patients who received at least one dose of study drug). This trial is registered with ClinicalTrials.gov, NCT02215616, and EudraCT, 2014-000418-75, and is now complete.

FINDINGS:

Between Oct 28, 2014, and June 19, 2018, 352 adults with Huntington's disease (179 [51%] men and 173 [49%] women; mean age 43·9 [SD 7·6] years and 340 [97%] White) were randomly assigned: 107 to laquinimod 0·5 mg, 107 to laquinimod 1·0 mg, 30 to laquinimod 1·5 mg, and 108 to matching placebo. Least squares mean change from baseline in UHDRS-TMS at week 52 was 1·98 (SE 0·83) in the laquinimod 1·0 mg group and 1·2 (0·82) in the placebo group (least squares mean difference 0·78 [95% CI -1·42 to 2·98], p=0·4853). Least squares mean change in caudate volume was 3·10% (SE 0·38) in the 1·0 mg group and 4·86% (0·38) in the placebo group (least squares mean difference -1·76% [95% CI -2·67 to -0·85]; p=0·0002). Laquinimod was well tolerated and there were no new safety findings. Serious adverse events were reported by eight (7%) patients on placebo, seven (7%) on laquinimod 0·5 mg, five (5%) on laquinimod 1·0 mg, and one (3%) on laquinimod 1·5 mg. There was one death, which occurred in the placebo group and was unrelated to treatment. The most frequent adverse events in all laquinimod dosed groups (0·5 mg, 1·0 mg, and 1·5 mg) were headache (38 [16%]), diarrhoea (24 [10%]), fall (18 [7%]), nasopharyngitis (20 [8%]), influenza (15 [6%]), vomiting (13 [5%]), arthralgia (11 [5%]), irritability (ten [4%]), fatigue (eight [3%]), and insomnia (eight [3%]).

INTERPRETATION:

Laquinimod did not show a significant effect on motor symptoms assessed by the UHDRS-TMS, but significantly reduced caudate volume loss compared with placebo at week 52. Huntington's disease has a chronic and slowly progressive course, and this study does not address whether a longer duration of laquinimod treatment could have produced detectable and meaningful changes in the clinical assessments.

FUNDING:

Teva Pharmaceutical Industries.

01 Mar 2024·The Lancet. Neurology

Laquinimod, Huntington's disease, and disease modification

Article

Author: Mestre, Tiago A

25 Jul 2023·International journal of pharmaceutics

In situ gel-forming oil as rectally delivering platform of hydrophobic therapeutics for ulcerative colitis therapy.

Article

Author: Lu, Kaili ; Zhao, Yingzheng ; Hu, Sunkuan ; Shangguan, Jianxun ; Xu, Jiawei ; Pan, Hanxiao ; Xu, Helin

Because of their poor water-soluble properties and non-specific distribution, most hydrophobic therapeutics had limited benefit for patients with ulcerative colitis. Herein, an in-situ oil-based gel has been developed as a rectal delivery vehicle for these therapeutics. In situ gel-forming oil (BBLG) was composed of soybean phosphatidyl choline (40%, w/w), glyceryl dioleate (50%, w/w), and ethanol (10%, w/w). The hydrophobic laquinimod (LAQ) as a model drug was easily dissolved in gel-forming oil and its solubility was reaching to 7 ± 0.1 mg/mL. Importantly, upon contact with the colonic fluids, the gel-forming oil was quickly transited to a semi-solid gel, adhering to the inflamed colon mucosa and forming a protective barrier. Transmission Electron Microscopy showed that the gel network was arranged by the connected lipid spheres and LAQ was non-crystally encapsulated into the lipid spheres. Moreover, the universal adhesive test showed that the adhesive force and the adhesive energy of BBLG toward fresh colon tissues were 711 ± 12 mN and 25 ± 2 J/m², which was 2.14-fold and 5-fold higher than that of the marketed Poloxamer 407 gel, respectively. Meanwhile, in vivo imaging confirmed that the retention time of BBLG in the colon lumen was more than 8 h after rectal administration. In vivo animal studies showed that BBLG also greatly enhanced the therapeutic impact of LAQ on TNBS-treated rats with ulcerative colitis, as evidenced by reduced disease activity index (DAI) scores and weight loss. Moreover, the colonic inflammation was significantly alleviated and the goblet cells were obliviously restored after treatment. Importantly, the gut mucosa barrier was largely repaired without any formation of fibrosis remodeling. Conclusively, in situ liquid gel may be a potential delivery system of hydrophobic medicines for ulcerative colitis.

News (Medical) associated with Laquinimod

01 Jun 2022

·www.globenewswire.com

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage

Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). In the study, the patients are treated with NAP for 4 consecutive days and with docetaxel at a standard dose on day 5 in 21-day treatment cycles. The first stage of this trial required a minimum of two responses out of ten patients to move to the second stage of the trial, which is now enrolling. For more information about the trial, visit www.clinicaltrials.gov. NCT04880863 We are pleased by these early encouraging observations and are excited to follow the progress of the trial, which is now enrolling in its second stage, says Erik Vahtola, Chief Medical Officer at Active Biotech. Patients with advanced NSCLC who have progressed on CPI and standard chemotherapy currently have limited treatment options and new treatment alternatives are needed.See also www.neotx.com for NeoTX’s communication related to this information. Helén Tuvesson President & CEO For further information, please contact: Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com This information is information that Active Biotech is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 14.00 pm. CET on June 1, 2022. Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information. About NeoTX NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company’s lead TTS molecule, naptumomab estafenatox is currently in clinical development for advanced solid tumors (clinicaltrials.gov/NCT039883954 and NCT04880863). Please visit www.neotx.com for more information. Naptumomab was licensed from Active Biotech to NeoTX Therapeutics Ltd in 2016. NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement. Active Biotech AB(Corp. Reg. No. 556223-9227)Scheelevägen 22, SE-223 63 Lund, SwedenTel: +46 (0)46 19 20 00 Attachment 220601_phase IIa clinical trial naptumomab in combination with docetaxel

First in ClassImmunotherapySmall molecular drugCollaborate

03 Oct 2021

·www.biospace.com

Active Biotech: Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. Ten patients have been treated with increasing doses of tasquinimod, which was generally well tolerated. The optimal dose and schedule of tasquinimod, when used as a single agent in patients with multiple myeloma has been established at 1 mg per day after a one-week run in of 0.5 mg daily. This is similar to the treatment schedule used in previous studies of tasquinimod. The trial will now advance to a previously planned combination part, in which treatment with tasquinimod will be tested in patients with multiple myeloma together with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd). Once an optimal dose and schedule of tasquinimod for the IRd combination is established, an expansion cohort will be recruited to further document the biological activity of tasquinimod in myeloma patients. Key secondary endpoints will include antimyeloma activity using the response criteria of the International Myeloma Working Group. The study is conducted in a partnership with the Abramson Cancer Center of the University of Pennsylvania, with Dr. Dan Vogl as principal investigator. For more information about the study please visit clinical clinicaltrials.gov (NCT04405167). "We are pleased to have concluded the first part of this trial, confirming the previous safety pro tasquinimod in patients with multiple myeloma and defining an optimal dose and schedule for tasquinimod in this patient population. The patients included in this study phase were heavily pre-treated, with a median of 8 prior lines of therapy; 8 of the 10 patients were triple-class refractory to Imids, proteasome inhibitors, and anti-CD38 monoclonal antibodies. While none of the patients formally achieved a partial response, two patients with progressive myeloma at study entry achieved significant periods of stable disease on single-agent tasquinimod therapy. This suggests that tasquinimod has anti-myeloma activity in patients with advanced disease that is resistant to established therapies. These results enable us to advance into the combination part of the study, in which tasquinimod will be combined with a standard anti-myeloma treatment regimen. Our preclinical laboratory models suggest that this combination strategy may be a particularly effective way to utilize tasquinimod in myeloma therapy." says Dr. Dan Vogl, Principal Investigator. “We are enthusiastic to have reached this milestone and can conclude the first phase of this study. Based on the established safety data together with the encouraging anti-myeloma activities observed, we look forward to the continuation of the study. In the coming phase, tasquinimod will be evaluated in combination with ixazomib, lenalidomide, and dexamethasone (IRd), which already are established in the clinical practice. The use of tasquinimod, as a novel class of treatment for multiple myeloma, in combination with treatments used for earlier stage patients, is aligned with our current understanding of the mechanism of action of tasquinimod in these patients. ” says Helén Tuvesson, CEO, Active Biotech AB. Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 21:30 p.m. CET on October 3, 2021. About tasquinimod Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor's ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma. Tasquinimod has previously been studied as an anti-cancer agent in patients with solid cancers, including a phase 3 randomized trial in patients with metastatic prostate cancer. The tolerability of tasquinimod is well-characterized based on these previous experiences. Tasquinimod has demonstrated a clear therapeutic potential in preclinical models of multiple myeloma, when used as a single agent and in combination with standard multiple myeloma therapy. About multiple myeloma Multiple myeloma is an incurable blood cancer in which abnormal plasma cells in the bone marrow grow uncontrollably while other blood forming cells such as white and red blood cells and blood platelets are suppressed. This leads to anemia, infections, destruction of bone tissue and progressive loss of renal function. Despite new treatments have greatly improved survival of multiple myeloma patients, the biological heterogeneity of the disease and the emergence of drug resistance is a major challenge, and the medical need of innovative treatment modalities remains high. In 2017, 81000 new cases of multiple myeloma were diagnosed in the eight major markets. The global sales of drugs for multiple myeloma totaled USD 16 billion in 2017 and sales are expected to increase 48% by 2026 (ref Global Data 2019). Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Please visit for more information. Active Biotech AB (Corp. Reg. No. 556223-9227) Scheelevägen 22, SE-223 63 Lund, Sweden Tel: +46 (0)46 19 20 00 Attachment 211003_Tasquinimod clinical development in multiple myeloma

AntibodyFirst in ClassImmunotherapySmall molecular drugCollaborate

08 Jul 2021

·www.globenewswire.com

Active Biotech's partner NeoTX will host KOL webinar on

Lund, July 8 2021 - Active Biotech (Nasdaq Stockholm: ACTI) today provided information that its partner in the naptumomab project, NeoTX will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14th at 10 am eastern time (ET) The webinar will feature a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who will discuss New Frontiers for Checkpoint Inhibitors in Immuno-Oncology. NeoTX's management will also give an update on their Tumor Targeted Superantigen (TTS) platform’s lead candidate, naptumomab estafenatox (naptumomab) in overcoming resistance. Naptumomab is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management will be available to answer questions following the formal presentations. See also neotx.com/press-releases for NeoTX’s communication and for registration for the event. Since 2016, Active Biotech has a licensing agreement with NeoTX Therapeutics Ltd. for the worldwide development and commercialization of naptumomab for cancer therapy. For further information, please contact:Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.comHans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com This information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CET on July 8, 2021. Active BiotechActive Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to phase II for treatment of non-infectious uveitis during second half of 2021. Please visit www. Active Biotech AB (Corp. Reg. No. 556223-9227)Scheelevägen 22, SE-223 63 Lund, SwedenTel: +46 (0)46 19 20 00 Attachment

CollaborateFirst in ClassImmunotherapySmall molecular drug

100 Deals associated with Laquinimod

External Link

KEGG	Wiki	ATC	Drug Bank
D08938	Laquinimod	N07XX10	DB06685

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis	RU	Active Biotech AB	22 Aug 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis, Relapsing-Remitting	Phase 3	-	Teva Pharmaceutical Industries Ltd.	01 Jan 2014
Multiple Sclerosis, Relapsing-Remitting	Phase 3	-	Teva Branded Pharmaceutical Products R&D, Inc.	01 Jan 2014
Multiple sclerosis relapse	Phase 3	US	Teva Branded Pharmaceutical Products R&D, Inc.	13 Nov 2007
Multiple sclerosis relapse	Phase 3	AT	Teva Branded Pharmaceutical Products R&D, Inc.	13 Nov 2007
Multiple sclerosis relapse	Phase 3	BG	Teva Branded Pharmaceutical Products R&D, Inc.	13 Nov 2007
Multiple sclerosis relapse	Phase 3	CA	Teva Branded Pharmaceutical Products R&D, Inc.	13 Nov 2007
Multiple sclerosis relapse	Phase 3	CZ	Teva Branded Pharmaceutical Products R&D, Inc.	13 Nov 2007
Multiple sclerosis relapse	Phase 3	EE	Teva Branded Pharmaceutical Products R&D, Inc.	13 Nov 2007
Multiple sclerosis relapse	Phase 3	FR	Teva Branded Pharmaceutical Products R&D, Inc.	13 Nov 2007
Multiple sclerosis relapse	Phase 3	GE	Teva Branded Pharmaceutical Products R&D, Inc.	13 Nov 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01085084 (CTgov)	Phase 2	Arthritis \| Systemic Lupus Erythematosus	82	Placebo (Placebo)	qghvlfhtrv(julduwdvsc) = qwgibuifmf ynsktznvgs (ewhkelqzht, aincojlzqx - uiacrgcdrp) View more	-	07 Jul 2022
				Placebo+Laquinimod (Laquinimod 0.5 mg)	qghvlfhtrv(julduwdvsc) = ufrsmbubvp ynsktznvgs (ewhkelqzht, ywdramnfat - gjncvfvmvr) View more
NCT00605215 (CTgov)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	1,331	Placebo (Placebo)	fdalwdhoju(tosghaeuwm) = wyfbkwnldx zcvlgjqmlh (ycjsfspejn, kgjrtbrfsl - vrnlhxdind) View more	-	21 Apr 2022
				Laquinimod (Laquinimod)	fdalwdhoju(tosghaeuwm) = orumxomuix zcvlgjqmlh (ycjsfspejn, ldyxuqnhbg - cwnouljnqa) View more
NCT01085097 (CTgov)	Phase 2	Lupus Nephritis \| Systemic Lupus Erythematosus	46	Placebo+Methylprednisolone+mycophenolate mofetil+Prednisolone/Prednisone (Placebo)	ddsklfipju(xocisiuchu) = lxllezopre nndiynbrhy (ahapjzweeu, mopszxulyh - nmbechyrqk) View more	-	09 Mar 2022
				Placebo+Methylprednisolone+mycophenolate mofetil+Prednisolone/Prednisone+Laquinimod (Laquinimod 0.5 mg)	ddsklfipju(xocisiuchu) = lyjlcxrblt nndiynbrhy (ahapjzweeu, xtcuottfnp - kjlcsdlqbc) View more
NCT00509145 (CTgov)	Phase 3	Multiple sclerosis relapse	1,106	Laquinimod (Laquinimod)	taaillurgt(ufmdtzzdcy) = uptcbelndg xupadberdb (vlkocgtjsj, argukattfw - nxtwxxeddp) View more	-	02 Nov 2021
				Placebo (Placebo)	taaillurgt(ufmdtzzdcy) = xukgvvxdyb xupadberdb (vlkocgtjsj, kwwqbvimea - vosbfsiyft) View more
NCT01707992 (CONCERTO, Pubmed \| Mult Scler)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	2,199	Laquinimod 0.6 mg	yvfgehoqjx(kphwbsmhwz) = ocstubbgdr reuqdebnds (ufdygcljra )	Negative	11 Aug 2021
NCT02284568 (ARPEGGIO, Pubmed \| Ann Neurol)	Phase 2	Multiple Sclerosis, Primary Progressive	374	Laquinimod 0.6 mg	bnbhyoxqgp(lxpqixhelo): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001 View more	Negative	10 Jul 2020
				Placebo
MDS2019	Phase 2	Huntington Disease	-	Laquinimod 1.0 mg	ozqssojymz(tavnbarivb) = edovtvscei krpkepetnu (gdkmigtlxw )	Negative	22 Sep 2019
				Placebo	ozqssojymz(tavnbarivb) = jimimuuzhy krpkepetnu (gdkmigtlxw )
NCT02215616 (LEGATO-HD, CTgov)	Phase 2	Huntington Disease	352	Placebo (Placebo)	zqvfduzull(rbiimsfhap) = vimrxdwoof fvvsmsxevo (hnhfclhtgr, lzyicwikto - hzdouyvzul) View more	-	19 Jun 2019
				Placebo+Laquinimod (Laquinimod 0.5 mg)	zqvfduzull(rbiimsfhap) = uhpryukkqo fvvsmsxevo (hnhfclhtgr, vtsbcdrluk - hfcahmjdcs) View more
NCT02215616 (LEGATO-HD, AAN2019) Manual	Phase 2	Huntington Disease	-	laquinimod	spkomobmzt(hmqsukpoug): P-Value = 0.4853 View more	Negative	16 Apr 2019
				Placebo
NCT00745615 (CTgov)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	257	Laquinimod (Double-Blind: Laquinimod 0.3 mg)	zjrnkqlgsx(bmhvbdsjjf) = svrqhpijqp vpsljnwzau (ulcfahdpkb, sileoluqdw - pgbappcxrm) View more	-	27 Mar 2019
				Laquinimod (Double-Blind: Laquinimod 0.6 mg)	zjrnkqlgsx(bmhvbdsjjf) = qltzxwdzpj vpsljnwzau (ulcfahdpkb, dohwsuihfg - iqvimkgnxu) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis